Evaluating biomarkers for prognostic enrichment of clinical trials
- 10 August 2017
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 14 (6) , 629-638
Abstract
Background/Aims: A potential use of biomarkers is to assist in prognostic enrichment of clinical trials, where only patients at relatively higher risk for an outcome of interest are eligible for the trial. We investigated methods for evaluating biomarkers for prognostic enrichment. Methods: We identified five key considerations when considering a biomarker and a screening threshold for prognostic enrichment: (1) clinical trial sample size, (2) calendar time to enroll the trial, (3) total patient screening costs and the total per-patient trial costs, (4) generalizability of trial results, and (5) ethical evaluation of trial eligibility criteria. Items (1)–(3) are amenable to quantitative analysis. We developed the Biomarker Prognostic Enrichment Tool for evaluating biomarkers for prognostic enrichment at varying levels of screening stringency. Results: We demonstrate that both modestly prognostic and strongly prognostic biomarkers can improve trial metrics using Biomarker Prognostic Enrichment Tool. Biomarker Prognostic Enrichment Tool is available as a webtool at http://prognosticenrichment.com and as a package for the R statistical computing platform. Conclusion: In some clinical settings, even biomarkers with modest prognostic performance can be useful for prognostic enrichment. In addition to the quantitative analysis provided by Biomarker Prognostic Enrichment Tool, investigators must consider the generalizability of trial results and evaluate the ethics of trial eligibility criteria.Keywords
Funding Information
- National Institutes of Health (R01085757)
This publication has 21 references indexed in Scilit:
- Application of new acute kidney injury biomarkers in human randomized controlled trialsKidney International, 2016
- Renal cancer biomarkers: the promise of personalized careBMC Medicine, 2012
- Who should be included in a clinical trial of screening for bladder cancer?Cancer, 2012
- Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancerCancer Science, 2011
- Diagnostic and prognostic biomarkers of sepsis in critical careJournal of Antimicrobial Chemotherapy, 2011
- Enrichment of Clinical Study PopulationsClinical Pharmacology & Therapeutics, 2010
- The Development of Urinary Biomarkers for Kidney Disease Is the Search for Our Renal TroponinJournal of the American Society of Nephrology, 2009
- Emerging urinary biomarkers in the diagnosis of acute kidney injuryExpert Opinion on Medical Diagnostics, 2008
- Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 2005
- Molecular and genetic targets in early detectionCurrent Opinion in Oncology, 1999